DK1715890T3 - CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati - Google Patents
CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropatiInfo
- Publication number
- DK1715890T3 DK1715890T3 DK05713358T DK05713358T DK1715890T3 DK 1715890 T3 DK1715890 T3 DK 1715890T3 DK 05713358 T DK05713358 T DK 05713358T DK 05713358 T DK05713358 T DK 05713358T DK 1715890 T3 DK1715890 T3 DK 1715890T3
- Authority
- DK
- Denmark
- Prior art keywords
- diabetic nephropathy
- microalbuminuria
- ctgf
- therapy
- patients
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Microbiology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Vascular Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Mycology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hematology (AREA)
- Emergency Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Apparatus For Radiation Diagnosis (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54412104P | 2004-02-11 | 2004-02-11 | |
| US56101804P | 2004-04-08 | 2004-04-08 | |
| US57840104P | 2004-06-09 | 2004-06-09 | |
| US62080204P | 2004-10-20 | 2004-10-20 | |
| PCT/US2005/004367 WO2005077413A1 (en) | 2004-02-11 | 2005-02-11 | Ctgf as target for the therapy of diabetic nephropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK1715890T3 true DK1715890T3 (da) | 2008-11-17 |
Family
ID=34865408
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK05713358T DK1715890T3 (da) | 2004-02-11 | 2005-02-11 | CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati |
Country Status (14)
| Country | Link |
|---|---|
| US (2) | US20050214294A1 (de) |
| EP (2) | EP1977762A1 (de) |
| CN (1) | CN101884789A (de) |
| AT (1) | ATE400297T1 (de) |
| AU (1) | AU2005212371B2 (de) |
| CA (1) | CA2555789A1 (de) |
| DE (1) | DE602005008013D1 (de) |
| DK (1) | DK1715890T3 (de) |
| ES (1) | ES2311973T3 (de) |
| IL (1) | IL177437A (de) |
| NZ (1) | NZ549784A (de) |
| PL (1) | PL1715890T3 (de) |
| PT (1) | PT1715890E (de) |
| WO (1) | WO2005077413A1 (de) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1112088B1 (de) * | 1998-09-08 | 2010-10-27 | Henry Ford Health System | Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten |
| AU2006244148A1 (en) | 2005-05-05 | 2006-11-16 | Fibrogen, Inc. | Cardiovascular disease therapies |
| EP1968561B8 (de) * | 2005-12-22 | 2010-10-20 | Kiacta Sàrl | Behandlung von diabetischer nephropathie |
| WO2008078176A1 (en) * | 2006-12-22 | 2008-07-03 | Bellus Health (International) Limited | Methods, compounds, and compositions for treating metabolic disorders and diabetes |
| EP2545920A1 (de) * | 2007-08-22 | 2013-01-16 | Abbott GmbH & Co. KG | Therapie für Diabeteskomplikationen |
| NZ601660A (en) | 2008-08-25 | 2014-05-30 | Excaliard Pharmaceuticals Inc | Antisense oligonucleotides directed against connective tissue growth factor and uses thereof |
| US8946172B2 (en) | 2008-08-25 | 2015-02-03 | Excaliard Pharmaceuticals, Inc. | Method for reducing scarring during wound healing using antisense compounds directed to CTGF |
| KR101697396B1 (ko) | 2011-02-02 | 2017-01-17 | 엑스칼리아드 파마슈티컬즈, 인코포레이티드 | 결합 조직 성장 인자（ctgf）를 표적으로 하는 안티센스 화합물을 사용하여 켈로이드 또는 비후성 흉터를 치료하는 방법 |
| JP6612246B2 (ja) | 2013-11-28 | 2019-11-27 | シーエスエル、リミテッド | 腎症を処置する方法 |
| US11026625B2 (en) | 2017-08-08 | 2021-06-08 | Fresenius Medical Care Holdings, Inc. | Systems and methods for treating and estimating progression of chronic kidney disease |
| KR20200014684A (ko) | 2018-07-31 | 2020-02-11 | 주식회사 레모넥스 | Ctgf 발현 억제용 조성물 |
| CN109402127B (zh) * | 2018-09-29 | 2021-12-10 | 复旦大学附属眼耳鼻喉科医院 | 一组与结缔组织生长因子特异性结合的高亲和力核酸适配体及其应用 |
| CN109453191A (zh) * | 2018-12-06 | 2019-03-12 | 郑州大学第附属医院 | GSK-3β抑制剂及在糖尿病肾病干预新靶点的应用 |
| CN115925926A (zh) * | 2019-06-04 | 2023-04-07 | 江苏恒瑞医药股份有限公司 | 抗结缔组织生长因子抗体及其应用 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5408040A (en) | 1991-08-30 | 1995-04-18 | University Of South Florida | Connective tissue growth factor(CTGF) |
| US5770209A (en) | 1991-08-30 | 1998-06-23 | University Of South Florida | Acceleration of wound healing using connective tissue growth factor |
| US5876730A (en) | 1997-08-07 | 1999-03-02 | Childrens Hospital Research Foundation | Heparin-binding growth factor (HBGF) polypeptides |
| WO1999033878A1 (en) | 1997-12-25 | 1999-07-08 | Japan Tobacco Inc. | Monoclonal antibody against connective tissue growth factor and medicinal uses thereof |
| US20010006979A1 (en) | 1998-07-08 | 2001-07-05 | Richard Stratton | Method for treatment of fibrosis related diseases by the administration of prostacyclin derivatives |
| EP1112088B1 (de) | 1998-09-08 | 2010-10-27 | Henry Ford Health System | Verfahren zum Nachweis von Bindegewebswachstumsfaktor zur Diagnose von Nierkrankheiten |
| MXPA01004502A (es) | 1998-11-06 | 2002-09-18 | Fibrogen Inc | Factor de crecimiento de tejido conector (ctgf) y metodos de uso. |
| US6348329B1 (en) * | 1998-11-06 | 2002-02-19 | Fibrogen, Inc. | Nucleic acids encoding rat connective tissue growth factor (CTGF) and methods of use |
| DK1140969T3 (da) * | 1998-12-14 | 2007-09-17 | Univ Miami | Bindevævsvækstfaktorfragmenter og fremgangsmåder og anvendelser deraf |
| US6706491B1 (en) | 1999-04-09 | 2004-03-16 | The Board Of Trustees Of The University Of Illinois | Reagents and methods for identifying and modulating expression of genes regulated by p21 |
| US6965025B2 (en) | 2001-12-10 | 2005-11-15 | Isis Pharmaceuticals, Inc. | Antisense modulation of connective tissue growth factor expression |
| WO2003049773A1 (en) | 2001-12-11 | 2003-06-19 | Fibrogen, Inc. | Methods for inhibiting ocular processes |
| WO2003092584A2 (en) | 2002-04-30 | 2003-11-13 | Alcon, Inc. | Agents which regulate, inhibit, or modulate the activity and/or expression of connective tissue growth factor (ctgf) as a unique means to both lower intraocular pressure and treat glaucomatous retinopathies/optic neuropathies |
| US7405274B2 (en) | 2003-06-04 | 2008-07-29 | Fibrogen, Inc. | Connective tissue growth factor antibodies |
| EP1687410A4 (de) | 2003-10-07 | 2008-04-09 | Isis Pharmaceuticals Inc | Für das nieren-targeting optimierte antisense-oligonukleotide |
-
2005
- 2005-02-11 WO PCT/US2005/004367 patent/WO2005077413A1/en not_active Ceased
- 2005-02-11 NZ NZ549784A patent/NZ549784A/en unknown
- 2005-02-11 EP EP08011905A patent/EP1977762A1/de not_active Withdrawn
- 2005-02-11 EP EP05713358A patent/EP1715890B1/de not_active Expired - Lifetime
- 2005-02-11 CN CN2010102312546A patent/CN101884789A/zh active Pending
- 2005-02-11 US US11/057,323 patent/US20050214294A1/en not_active Abandoned
- 2005-02-11 ES ES05713358T patent/ES2311973T3/es not_active Expired - Lifetime
- 2005-02-11 PL PL05713358T patent/PL1715890T3/pl unknown
- 2005-02-11 DE DE602005008013T patent/DE602005008013D1/de not_active Expired - Lifetime
- 2005-02-11 AT AT05713358T patent/ATE400297T1/de active
- 2005-02-11 DK DK05713358T patent/DK1715890T3/da active
- 2005-02-11 AU AU2005212371A patent/AU2005212371B2/en not_active Ceased
- 2005-02-11 CA CA002555789A patent/CA2555789A1/en not_active Abandoned
- 2005-02-11 PT PT05713358T patent/PT1715890E/pt unknown
-
2006
- 2006-08-10 IL IL177437A patent/IL177437A/en active IP Right Grant
-
2010
- 2010-06-03 US US12/802,373 patent/US8314059B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| IL177437A (en) | 2013-06-27 |
| EP1977762A1 (de) | 2008-10-08 |
| US20100291098A1 (en) | 2010-11-18 |
| EP1715890B1 (de) | 2008-07-09 |
| EP1715890A1 (de) | 2006-11-02 |
| PL1715890T3 (pl) | 2009-01-30 |
| ES2311973T3 (es) | 2009-02-16 |
| US20050214294A1 (en) | 2005-09-29 |
| AU2005212371B2 (en) | 2010-05-13 |
| CN101884789A (zh) | 2010-11-17 |
| DE602005008013D1 (de) | 2008-08-21 |
| CA2555789A1 (en) | 2005-08-25 |
| WO2005077413A1 (en) | 2005-08-25 |
| NZ549784A (en) | 2008-06-30 |
| US8314059B2 (en) | 2012-11-20 |
| AU2005212371A1 (en) | 2005-08-25 |
| ATE400297T1 (de) | 2008-07-15 |
| IL177437A0 (en) | 2006-12-10 |
| HK1095762A1 (en) | 2007-05-18 |
| PT1715890E (pt) | 2008-10-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR0308928A (pt) | Uso de toxina botulìnica para o tratamento de doenças cardiovasculares, bem como composição para uso em um procedimento cardiovascular | |
| DK1715890T3 (da) | CTGF som mål for mikroalbuminuriterapi hos patienter med diabetisk nefropati | |
| NO20074999L (no) | Metode og preparat for behandling av perifere vaskulaere sykdommer | |
| EA201100335A1 (ru) | Производные пурина для применения при лечении связанных с fab заболеваний | |
| CY2016015I2 (el) | Αζετιδινες ως αναστολεις μεκ για τη θεραπευτικη αγωγη πολλαπλασιαστικων ασθενειων | |
| EA200802213A1 (ru) | Способы лечения заболеваний крови | |
| UY32030A (es) | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" | |
| CY1110889T1 (el) | C-αρυλο γλυκοζιτικοι sglt2 αναστολεις και μεθοδος για την παραγωγη τους | |
| ATE542823T1 (de) | 4,5-dihydro-ä1,2,4ütriazoloä4,3-füpteridine als plk1-proteinkinasehemmer zur behandlung proliferativer erkrankungen | |
| EA201000914A1 (ru) | Новые терапевтические подходы в лечении смт и связанных с ней расстройств | |
| HUS1500058I1 (hu) | Benzoxazint tartalmazó gyógyszer-kombináció légúti betegségek kezelésére | |
| AP2378A (en) | Sulfonamide derivatives for the treatment of diseases. | |
| PL1708991T3 (pl) | Pochodne sulfonoamidu do leczenia chorób | |
| CY1110620T1 (el) | Μεθοδος θεραπειας οξειας παραρρινοκολπιτιδας | |
| ATE446102T1 (de) | Behandlung von gewichtsverlust bei patienten mit entzündlichen darmerkrankungen mittels s. boulardii | |
| EP1958648A4 (de) | Therapeutisches verfahren für blutgerinnungsstörungen | |
| EE200300366A (et) | Meetodid nahahaiguste ravimiseks või tõkestamiseks CD2-siduvate vahendite abil | |
| EA200700407A1 (ru) | Производные хиназолина и их использования при лечении тромбоцитемии | |
| CY1109666T1 (el) | Μεθοδος θεραπειας διαταραχων ξηροφθαλμιας και ραγοειδιτιδας | |
| BR0313588A (pt) | Métodos para o tratamento da demência com base em apo e genótipo | |
| DE502006006466D1 (de) | Eisen(iii) komplex-verbindungen zur oralen behandlung von eisenmangel bei patienten mit chronischen entzündlichen darmerkrankungen | |
| DK1889920T3 (da) | In vitro fremgangsmåde atil identifikation af forbindelse atil cancerterapi | |
| ITRM20050179A1 (it) | Composizione impiegabile per il trattamento delle patologie paradontali. | |
| DE602008004556D1 (de) | Zusammensetzungen und verfahren zum nachweis von störungen in verbindung mit histamin | |
| ATE557102T1 (de) | Methoden zur vorhersage der wirksamkeit von interferon therapie bei multiple sklerose patienten und methoden zur diagnose der krankheit |